Abacus Life and Lorisco Life Announce Launch of PREADISAN to Improve Health Predictions
Abacus Life and Lorisco Life Announce Launch of PREADISAN to Improve Health Predictions
-
New partnership leverages PREADISAN, the cutting-edge health prediction platform using machine learning and modern proteomics
- Applies novel big data analytics tools to the Abacus portfolio of services
- Lorisco's risk scores will enable a more personalized approach to longevity and actuarial technology to maximize value for Abacus' clients
- 新合作运用PREADISAN,这一先进的健康预测平台利用机器学习和现代蛋白质组学。
- 将新颖的大数据分析工具应用于Abacus服务组合。
- Lorisco的风险评分将为Abacus的客户提供更个性化的养老和精算技术方案,以最大化价值。
ORLANDO, Fla and NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) --
2024年8月19日,佛罗里达州奥兰多和纽约(环球新闻社)——
Abacus Life, Inc. ("Abacus") (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, and Lorisco Life LLC ("Lorisco"), a health prediction company using modern proteomics and machine learning to accurately forecast health events, today announced a new partnership and product launch to revolutionize longevity-based health prediction and actuarial technology.
先锋性替代资产管理公司Abacus Life, Inc.(“Abacus”)(纳斯达克证券交易所:ABL)和Lorisco Life LLC(“Lorisco”)——一家利用现代蛋白质组学和机器学习精确预测健康事件的健康预测公司,今天宣布新合作及新产品发布,以彻底改革基于长寿的健康预测和精算技术。
The Lorisco PREADISAN risk score is a novel assessment and planning tool that generates individualized insights beyond traditional statistics-based life expectancy opinions. The PREADISAN risk score introduces blood-based proteomic biomarker analysis coupled with clinically driven artificial intelligence (AI) models that assess mortality risks. The PREADISAN risk score is a first of its kind tool that integrates biological insights with the assessment of mortality risk over time.
Lorisco PREADISAN风险评分是一个新颖的评估和规划工具,生成超越传统统计学寿命预测意见的个性化见解。PREADISAN风险评分结合了基于血液的蛋白质组学生物标志分析和臨床驅動的人工智能(AI)模型,来评估死亡风险。PREADISAN风险评分是一种首个将生物学见解融入对死亡风险的评估的工具,融合了传统精算因素和现代蛋白质组学标志物的健康风险模型,使Abacus能够为客户提供量身定制的解决方案。
Abacus continues to develop and shape the future of technology in life settlements, longevity and actuarial technology. This partnership provides customized financial offerings for users based on Lorisco's cutting-edge health prediction platform. Abacus' leading capabilities are further enhanced with the launch of PREADISAN, a risk score forecasting longevity and health outcomes with unprecedented personalization. Lorisco's proprietary machine learning algorithms use health risk models that incorporate modern proteomic markers on top of traditional actuarial factors, together enabling Abacus to offer bespoke solutions tailored to the client.
Abacus一直在推动并塑造寿险结算、养老和精算技术的未来。这一合作为用户提供了基于Lorisco先进健康预测平台的定制化金融产品。PREADISAN的推出进一步增强了Abacus的领先能力,这是一种风险评分,可预测长寿和健康结果,并具有前所未有的个性化。Lorisco专有的机器学习算法使用健康风险模型,该模型在传统精算因素之上包含现代蛋白质组学标志物,使Abacus能够提供为客户量身定制的解决方案。
"We are proud to be partnering with Abacus Life to enable how health predictions are customized for end users through proteomics and machine learning," said Howard Sams, Lorisco Life Chief Executive Officer. "The PREADISAN risk score enables the Abacus team to offer an unprecedented level of tailored solutions for their clients."
“我们很自豪能与Abacus Life合作,通过蛋白质组学和机器学习为终端用户定制健康预测方法,”Lorisco Life首席执行官霍华德•桑姆斯(Howard Sams)表示。“PREADISAN风险评分使Abacus团队能够为客户提供前所未有的量身定制解决方案。」
"We are proud to enable a more personalized approach to longevity and actuarial technology for our partners and clients," stated Jay Jackson, Abacus Chairman and Chief Executive Officer. "PREADISAN forecasts will further aid the focus of longevity and health in the future of financial planning and life settlements."
“我们很自豪能为我们的合作伙伴和客户提供更个性化的养老和精算技术方法,”Abacus主席兼首席执行官杰伊·杰克逊(Jay Jackson)表示。“PREADISAN的预测将进一步帮助集中长寿和健康在未来的财务规划和寿险结算上。」
Abacus will apply the risk scores to life and financial planning to design better financial products and allocations to their clients. Clients will also obtain more customized retirement planning and risk management insights from Abacus.
Abacus将把风险评分应用于寿险和财务规划,为其客户设计更好的金融产品和分配方案。客户还将从Abacus获得更加个性化的养老规划和风险管理见解。
About Abacus Life, Inc. ()
Abacus is a leading global alternative asset manager and market maker that specializes in the use of advanced longevity and actuarial technology to purchase life insurance policies from consumers seeking liquidity, while creating a high-returning asset class of insurance products, uncorrelated to market fluctuations, for institutional investors. With more than $2 billion in assets under management, Abacus is the only publicly traded licensed life policy origination company and asset manager.
关于Abacus Life, Inc. ()
Abacus是一家领先的全球另类资产管理公司和市场制造商,专门使用先进的寿命和精算技术从寻求流动性的消费者购买人寿保险,并为机构投资者创造一个不受市场波动影响的高收益保险产品资产类别。Abacus拥有超过20亿美元的资产管理规模,是唯一一家公开交易的保险单起始公司和资产管理公司。
The company's pioneering experience in the life planning space has created growth into new verticals. The longevity-based wealth management service and investment offerings, called ABL Wealth, uses Abacus' decades of data and proprietary algorithms to help financial advisors create more customized plans for clients and access to uncorrelated investment funds. The ground-breaking technology service, called ABL Tech, provides advanced real-time data tracking and analysis for pensions funds, governments, insurance companies, retirement associations and more. With each new channel, Abacus is revolutionizing the future of life insurance.
公司在寿命规划领域的开创性经验已经推动了到新垂直市场的发展。以长寿为基础的财富管理服务和投资产品(称为ABL Wealth),利用Abacus几十年的数据和专有算法,帮助理财顾问为客户创建更加定制化的计划,以及访问不相关的投资基金。创新的技术服务(称为ABL Tech)为退休金基金、政府、保险公司、退休联盟等提供高级的实时数据跟踪和分析。随着每一个新通道的推出,Abacus正在提供革命性的生命保险未来。
About Lorisco Life, LLC ()
关于Lorisco Life, LLC ()
Lorisco is empowering a healthier future by providing accessible, customized risk scores for longevity and chronic disease at scale using proteomics and predictive modeling. The proprietary machine learning algorithms of Lorisco use statistical models of health risk that incorporate traditional factors and modern proteomic markers. Using a common platform, Lorisco is launching businesses that leverage its algorithms in financial services. Lorisco is a subsidiary of Health Outlook Corp. The lab used for Lorisco's PREADISANTM risk score is a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The results of the PREADISAN risk score should only be used for informational purposes. The results are not intended to diagnose or treat any medical condition and do not constitute medical advice.
Lorisco通过提供利用蛋白质组学和预测建模可大量生成长寿和慢性病风险评分的有益和定制化评分,为推动更健康的未来进行授权。Lorisco的专有机器学习算法使用包含传统因素和现代蛋白质组标志物的健康风险统计模型。Lorisco正在利用一个共同的平台,在金融服务市场上推出利用其算法的企业。Lorisco是Health Outlook Corp.的一个子公司。Lorisco PREADISANtm风险评分所使用的实验室是一家根据1988年临床实验室改进法案(CLIA)认证的临床实验室。PREADISAN风险评分的结果仅用于信息目的。结果不旨在诊断或治疗任何医学状况,也不构成医疗建议。
Forward-Looking Statements
All statements in this press release (and oral statements made regarding the subjects of this press release) other than historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors that could cause actual results to differ materially from such statements, many of which are outside the control of Abacus. Forward-looking information includes but is not limited to statements regarding: Abacus's financial and operational outlook; Abacus's operational and financial strategies, including planned growth initiatives and the benefits thereof, Abacus's ability to successfully effect those strategies, and the expected results therefrom. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "expect," "intend," "anticipate," "goals," "prospects," "will," "would," "will continue," "will likely result," and similar expressions (including the negative versions of such words or expressions).
前瞻性声明
本新闻稿中的所有声明(以及关于本新闻稿主题的口头声明)均不涉及历史事实,其为根据1934年修正后的证券交易法第21条(“21E”)进行的前瞻性声明。这些前瞻性声明基于有关未来事件的一些假设,并受一些不确定性和因素的影响,这些因素可能导致实际结果与此类声明不同,其中许多因素都超出了Abacus的控制范围。前瞻性信息包括但不限于有关以下事项的声明:Abacus的财务和运营前景;Abacus的运营和财务战略,包括计划的增长举措及其带来的利益,Abacus成功实施这些战略的能力以及预期的结果。这些前瞻性声明通常由以下字眼或表达方式(包括这些字眼或表达方式的否定版本)识别出来:
While Abacus believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in predicting certain important factors that could impact the future performance or results of its business. The factors that could cause results to differ materially from those indicated by such forward-looking statements include, but are not limited to: the fact that Abacus's loss reserves are based on estimates and may be inadequate to cover its actual losses; the failure to properly price Abacus's insurance policies; the geographic concentration of Abacus's business; the cyclical nature of Abacus's industry; the impact of regulation on Abacus's business; the effects of competition on Abacus's business; the failure of Abacus's relationships with independent agencies; the failure to meet Abacus's investment objectives; the inability to raise capital on favorable terms or at all; the effects of acts of terrorism; and the effectiveness of Abacus's control environment, including the identification of control deficiencies.
虽然Abacus认为有关未来事件的假设是合理的,但它提醒说,预测可能对公司未来业绩或结果产生重大影响的某些重要因素存在内在困难。可能导致结果与所示前瞻性声明不同的因素包括,但不限于:Abacus的损失准备金是基于估计值,可能不足以覆盖其实际损失;未能正确定价Abacus的保险单;Abacus业务的地理集中度;Abacus行业的周期性,管理层;法规对Abacus业务的影响;竞争对Abacus业务的影响;Abacus与独立经纪关系的失败;未能达到Abacus的投资目标;不能以有利的条件或根本无法筹集资本;恐怖主义行为的影响;以及Abacus的控制环境的有效性,包括识别控制缺陷。
These forward-looking statements are also affected by the risk factors, forward-looking statements and challenges and uncertainties set forth in documents filed by Abacus with the U.S. Securities and Exchange Commission from time to time, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and subsequent periodic reports. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Abacus cautions you not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abacus assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Abacus does not give any assurance that it will achieve its expectations.
这些前瞻性声明也受到Abacus从时间到时间向美国证券交易委员会提交的文件中报告的风险因素,前瞻性声明,挑战和不确定性的影响,例如年度报告10-K和季度报告10-Q以及随后的定期报告影响。这些文件确定并解决了其他重要的风险和不确定性,可能导致实际事件和结果与前瞻性声明所包含的不同,Abacus提醒您不要过分依赖本新闻稿所载的前瞻性声明。前瞻性声明仅于它们发表的日期。读者被告诫不要过分依赖前瞻性声明,并且Abacus假定没有义务并且除了法律要求外,不打算更新或修订这些前瞻性声明,不管是因为新信息、未来事件还是其他原因。Abacus不保证将达到其预期。
Contacts:
联系人:
Abacus Life Investor Relations
investors@abacuslife.com
no translation needed
investors@abacuslife.com
Abacus Life Public Relations
press@abacuslife.com
Abacus Life公共关系
press@abacuslife.com
Lorisco Life Public Relations
contact@lorisco.life
Lorisco Life公关
contact@lorisco.life